Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway
Objectives. Recently, immunotherapy and microRNA have shown much more promises in oncology research, inspiring new hope for a cure for various malignancies. Specifically, the function and mechanisms of action of pembrolizumab have been investigated in many cancers, but not in laryngeal squamous cell...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2021, Vol.2021, p.2342784-6 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6 |
|---|---|
| container_issue | |
| container_start_page | 2342784 |
| container_title | BioMed research international |
| container_volume | 2021 |
| creator | Chen, Hui Guo, Yang Huang, Jiameng Zhou, Liang |
| description | Objectives. Recently, immunotherapy and microRNA have shown much more promises in oncology research, inspiring new hope for a cure for various malignancies. Specifically, the function and mechanisms of action of pembrolizumab have been investigated in many cancers, but not in laryngeal squamous cell carcinoma. The present study thus focused on the effect of hsa-miR-128a on pembrolizumab in laryngeal cancer cells as well as tried to elucidate the mechanisms that may mediate this effect. Methods. Hep2 and AMC-HN8 cell lines were utilized to create stable cell lines that overexpressing hsa-miR-128a. Using the immunotherapy assay, the contribution of hsa-miR-128a to pembrolizumab sensitivity was evaluated. By performing the dual luciferase assay and quantitative real-time polymerase chain reaction, the possible mechanisms of hsa-miR-128a were identified. Results. Hsa-miR-128a was overexpressed in laryngeal cancer cell lines successfully. The immunotherapy assay revealed that upregulating hsa-miR-128a augmented the effect of pembrolizumab. Moreover, hsa-miR-128a targeted BMI-1 and might played a role in the p53 pathway. Conclusion. Hsa-miR-128a boosted the effect of pembrolizumab on laryngeal cancer cells, perhaps via the p53 pathway. Therefore, hsa-miR-128a might be a novel target in laryngeal cancer treatment. |
| doi_str_mv | 10.1155/2021/2342784 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7997759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A696930489</galeid><sourcerecordid>A696930489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-30240d7e7433ccc4fbb0d52c77a8e915a4453d5c84b65a05b8d8647fe58cd5943</originalsourceid><addsrcrecordid>eNp9kc9LHDEYhofSUsV667kEemxH83OSXAqy2CosVETP4ZtMZiYyk9kmM4r96xu769pezCWBPHl4v7xF8ZHgE0KEOKWYklPKOJWKvykOKSO8rAgnb_dnxg6K45TucF6KVFhX74sDxqQmrCKHRbjdRNctA8w-dKhPUI7-uiRUAboMNjpIrkFz79B52zo7JzS16MqNdZwG_3sZoUZTQGuIj6FzMKAVBOsiWrlhSOjew9-nG8HQFcz9Azx-KN61MCR3vNuPitvv5zeri3L988fl6mxdWoH5XDJMOW6kk5wxay1v6xo3glopQTlNBHAuWCOs4nUlAItaNarisnVC2UZozo6Kb1vvZqlH11gX5giD2UQ_5qxmAm_-vwm-N910b6TWUgqdBZ93gjj9Wlyazd20xJAzGypw_kalKH-hOhic8aGdssyOPllzVulKM8yVfp1SnGgiNcvU1y1l45RSdO0-LcHmqWzzVLbZlZ3xT_9OuIefq83Aly3Q-9DAg39d9wcNBa5w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506098824</pqid></control><display><type>article</type><title>Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Hui ; Guo, Yang ; Huang, Jiameng ; Zhou, Liang</creator><contributor>Xu, Zhenbo ; Zhenbo Xu</contributor><creatorcontrib>Chen, Hui ; Guo, Yang ; Huang, Jiameng ; Zhou, Liang ; Xu, Zhenbo ; Zhenbo Xu</creatorcontrib><description>Objectives. Recently, immunotherapy and microRNA have shown much more promises in oncology research, inspiring new hope for a cure for various malignancies. Specifically, the function and mechanisms of action of pembrolizumab have been investigated in many cancers, but not in laryngeal squamous cell carcinoma. The present study thus focused on the effect of hsa-miR-128a on pembrolizumab in laryngeal cancer cells as well as tried to elucidate the mechanisms that may mediate this effect. Methods. Hep2 and AMC-HN8 cell lines were utilized to create stable cell lines that overexpressing hsa-miR-128a. Using the immunotherapy assay, the contribution of hsa-miR-128a to pembrolizumab sensitivity was evaluated. By performing the dual luciferase assay and quantitative real-time polymerase chain reaction, the possible mechanisms of hsa-miR-128a were identified. Results. Hsa-miR-128a was overexpressed in laryngeal cancer cell lines successfully. The immunotherapy assay revealed that upregulating hsa-miR-128a augmented the effect of pembrolizumab. Moreover, hsa-miR-128a targeted BMI-1 and might played a role in the p53 pathway. Conclusion. Hsa-miR-128a boosted the effect of pembrolizumab on laryngeal cancer cells, perhaps via the p53 pathway. Therefore, hsa-miR-128a might be a novel target in laryngeal cancer treatment.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2021/2342784</identifier><identifier>PMID: 33791361</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Analysis ; Antibodies ; Antibodies, Monoclonal, Humanized - pharmacology ; Assaying ; Biotechnology ; Bmi protein ; Cancer ; Cancer cells ; Cancer therapies ; Cell Line, Tumor ; Cellular signal transduction ; Chemotherapy ; Drug therapy ; Enzymes ; Gene expression ; Gene Expression Regulation, Neoplastic - drug effects ; Genetic aspects ; Health aspects ; Humans ; Identification and classification ; Immunotherapy ; Laryngeal cancer ; Laryngeal Neoplasms - drug therapy ; Laryngeal Neoplasms - genetics ; Laryngeal Neoplasms - metabolism ; Laryngeal Neoplasms - pathology ; Medical prognosis ; Medical research ; Metastasis ; MicroRNA ; MicroRNAs - biosynthesis ; MicroRNAs - genetics ; miRNA ; Monoclonal antibodies ; p53 Protein ; Patient outcomes ; Pembrolizumab ; Physiological aspects ; Plasmids ; Polymerase chain reaction ; Properties ; Ribonucleic acid ; RNA ; RNA, Neoplasm - biosynthesis ; RNA, Neoplasm - genetics ; Sensitivity analysis ; Signal Transduction - drug effects ; Squamous cell carcinoma ; Targeted cancer therapy ; Tumor cell lines ; Tumor proteins ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism ; Up-Regulation - drug effects</subject><ispartof>BioMed research international, 2021, Vol.2021, p.2342784-6</ispartof><rights>Copyright © 2021 Hui Chen et al.</rights><rights>COPYRIGHT 2021 John Wiley & Sons, Inc.</rights><rights>Copyright © 2021 Hui Chen et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Hui Chen et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-30240d7e7433ccc4fbb0d52c77a8e915a4453d5c84b65a05b8d8647fe58cd5943</citedby><cites>FETCH-LOGICAL-c504t-30240d7e7433ccc4fbb0d52c77a8e915a4453d5c84b65a05b8d8647fe58cd5943</cites><orcidid>0000-0003-3314-8653 ; 0000-0001-5268-9645 ; 0000-0002-8588-2959</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997759/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997759/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33791361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Xu, Zhenbo</contributor><contributor>Zhenbo Xu</contributor><creatorcontrib>Chen, Hui</creatorcontrib><creatorcontrib>Guo, Yang</creatorcontrib><creatorcontrib>Huang, Jiameng</creatorcontrib><creatorcontrib>Zhou, Liang</creatorcontrib><title>Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Objectives. Recently, immunotherapy and microRNA have shown much more promises in oncology research, inspiring new hope for a cure for various malignancies. Specifically, the function and mechanisms of action of pembrolizumab have been investigated in many cancers, but not in laryngeal squamous cell carcinoma. The present study thus focused on the effect of hsa-miR-128a on pembrolizumab in laryngeal cancer cells as well as tried to elucidate the mechanisms that may mediate this effect. Methods. Hep2 and AMC-HN8 cell lines were utilized to create stable cell lines that overexpressing hsa-miR-128a. Using the immunotherapy assay, the contribution of hsa-miR-128a to pembrolizumab sensitivity was evaluated. By performing the dual luciferase assay and quantitative real-time polymerase chain reaction, the possible mechanisms of hsa-miR-128a were identified. Results. Hsa-miR-128a was overexpressed in laryngeal cancer cell lines successfully. The immunotherapy assay revealed that upregulating hsa-miR-128a augmented the effect of pembrolizumab. Moreover, hsa-miR-128a targeted BMI-1 and might played a role in the p53 pathway. Conclusion. Hsa-miR-128a boosted the effect of pembrolizumab on laryngeal cancer cells, perhaps via the p53 pathway. Therefore, hsa-miR-128a might be a novel target in laryngeal cancer treatment.</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Antibodies, Monoclonal, Humanized - pharmacology</subject><subject>Assaying</subject><subject>Biotechnology</subject><subject>Bmi protein</subject><subject>Cancer</subject><subject>Cancer cells</subject><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Cellular signal transduction</subject><subject>Chemotherapy</subject><subject>Drug therapy</subject><subject>Enzymes</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Immunotherapy</subject><subject>Laryngeal cancer</subject><subject>Laryngeal Neoplasms - drug therapy</subject><subject>Laryngeal Neoplasms - genetics</subject><subject>Laryngeal Neoplasms - metabolism</subject><subject>Laryngeal Neoplasms - pathology</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>MicroRNA</subject><subject>MicroRNAs - biosynthesis</subject><subject>MicroRNAs - genetics</subject><subject>miRNA</subject><subject>Monoclonal antibodies</subject><subject>p53 Protein</subject><subject>Patient outcomes</subject><subject>Pembrolizumab</subject><subject>Physiological aspects</subject><subject>Plasmids</subject><subject>Polymerase chain reaction</subject><subject>Properties</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Neoplasm - biosynthesis</subject><subject>RNA, Neoplasm - genetics</subject><subject>Sensitivity analysis</subject><subject>Signal Transduction - drug effects</subject><subject>Squamous cell carcinoma</subject><subject>Targeted cancer therapy</subject><subject>Tumor cell lines</subject><subject>Tumor proteins</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Up-Regulation - drug effects</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc9LHDEYhofSUsV667kEemxH83OSXAqy2CosVETP4ZtMZiYyk9kmM4r96xu769pezCWBPHl4v7xF8ZHgE0KEOKWYklPKOJWKvykOKSO8rAgnb_dnxg6K45TucF6KVFhX74sDxqQmrCKHRbjdRNctA8w-dKhPUI7-uiRUAboMNjpIrkFz79B52zo7JzS16MqNdZwG_3sZoUZTQGuIj6FzMKAVBOsiWrlhSOjew9-nG8HQFcz9Azx-KN61MCR3vNuPitvv5zeri3L988fl6mxdWoH5XDJMOW6kk5wxay1v6xo3glopQTlNBHAuWCOs4nUlAItaNarisnVC2UZozo6Kb1vvZqlH11gX5giD2UQ_5qxmAm_-vwm-N910b6TWUgqdBZ93gjj9Wlyazd20xJAzGypw_kalKH-hOhic8aGdssyOPllzVulKM8yVfp1SnGgiNcvU1y1l45RSdO0-LcHmqWzzVLbZlZ3xT_9OuIefq83Aly3Q-9DAg39d9wcNBa5w</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Chen, Hui</creator><creator>Guo, Yang</creator><creator>Huang, Jiameng</creator><creator>Zhou, Liang</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3314-8653</orcidid><orcidid>https://orcid.org/0000-0001-5268-9645</orcidid><orcidid>https://orcid.org/0000-0002-8588-2959</orcidid></search><sort><creationdate>2021</creationdate><title>Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway</title><author>Chen, Hui ; Guo, Yang ; Huang, Jiameng ; Zhou, Liang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-30240d7e7433ccc4fbb0d52c77a8e915a4453d5c84b65a05b8d8647fe58cd5943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Antibodies, Monoclonal, Humanized - pharmacology</topic><topic>Assaying</topic><topic>Biotechnology</topic><topic>Bmi protein</topic><topic>Cancer</topic><topic>Cancer cells</topic><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Cellular signal transduction</topic><topic>Chemotherapy</topic><topic>Drug therapy</topic><topic>Enzymes</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Immunotherapy</topic><topic>Laryngeal cancer</topic><topic>Laryngeal Neoplasms - drug therapy</topic><topic>Laryngeal Neoplasms - genetics</topic><topic>Laryngeal Neoplasms - metabolism</topic><topic>Laryngeal Neoplasms - pathology</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>MicroRNA</topic><topic>MicroRNAs - biosynthesis</topic><topic>MicroRNAs - genetics</topic><topic>miRNA</topic><topic>Monoclonal antibodies</topic><topic>p53 Protein</topic><topic>Patient outcomes</topic><topic>Pembrolizumab</topic><topic>Physiological aspects</topic><topic>Plasmids</topic><topic>Polymerase chain reaction</topic><topic>Properties</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Neoplasm - biosynthesis</topic><topic>RNA, Neoplasm - genetics</topic><topic>Sensitivity analysis</topic><topic>Signal Transduction - drug effects</topic><topic>Squamous cell carcinoma</topic><topic>Targeted cancer therapy</topic><topic>Tumor cell lines</topic><topic>Tumor proteins</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Hui</creatorcontrib><creatorcontrib>Guo, Yang</creatorcontrib><creatorcontrib>Huang, Jiameng</creatorcontrib><creatorcontrib>Zhou, Liang</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Hui</au><au>Guo, Yang</au><au>Huang, Jiameng</au><au>Zhou, Liang</au><au>Xu, Zhenbo</au><au>Zhenbo Xu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>2342784</spage><epage>6</epage><pages>2342784-6</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Objectives. Recently, immunotherapy and microRNA have shown much more promises in oncology research, inspiring new hope for a cure for various malignancies. Specifically, the function and mechanisms of action of pembrolizumab have been investigated in many cancers, but not in laryngeal squamous cell carcinoma. The present study thus focused on the effect of hsa-miR-128a on pembrolizumab in laryngeal cancer cells as well as tried to elucidate the mechanisms that may mediate this effect. Methods. Hep2 and AMC-HN8 cell lines were utilized to create stable cell lines that overexpressing hsa-miR-128a. Using the immunotherapy assay, the contribution of hsa-miR-128a to pembrolizumab sensitivity was evaluated. By performing the dual luciferase assay and quantitative real-time polymerase chain reaction, the possible mechanisms of hsa-miR-128a were identified. Results. Hsa-miR-128a was overexpressed in laryngeal cancer cell lines successfully. The immunotherapy assay revealed that upregulating hsa-miR-128a augmented the effect of pembrolizumab. Moreover, hsa-miR-128a targeted BMI-1 and might played a role in the p53 pathway. Conclusion. Hsa-miR-128a boosted the effect of pembrolizumab on laryngeal cancer cells, perhaps via the p53 pathway. Therefore, hsa-miR-128a might be a novel target in laryngeal cancer treatment.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>33791361</pmid><doi>10.1155/2021/2342784</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3314-8653</orcidid><orcidid>https://orcid.org/0000-0001-5268-9645</orcidid><orcidid>https://orcid.org/0000-0002-8588-2959</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2021, Vol.2021, p.2342784-6 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7997759 |
| source | MEDLINE; PubMed Central Open Access; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
| subjects | Analysis Antibodies Antibodies, Monoclonal, Humanized - pharmacology Assaying Biotechnology Bmi protein Cancer Cancer cells Cancer therapies Cell Line, Tumor Cellular signal transduction Chemotherapy Drug therapy Enzymes Gene expression Gene Expression Regulation, Neoplastic - drug effects Genetic aspects Health aspects Humans Identification and classification Immunotherapy Laryngeal cancer Laryngeal Neoplasms - drug therapy Laryngeal Neoplasms - genetics Laryngeal Neoplasms - metabolism Laryngeal Neoplasms - pathology Medical prognosis Medical research Metastasis MicroRNA MicroRNAs - biosynthesis MicroRNAs - genetics miRNA Monoclonal antibodies p53 Protein Patient outcomes Pembrolizumab Physiological aspects Plasmids Polymerase chain reaction Properties Ribonucleic acid RNA RNA, Neoplasm - biosynthesis RNA, Neoplasm - genetics Sensitivity analysis Signal Transduction - drug effects Squamous cell carcinoma Targeted cancer therapy Tumor cell lines Tumor proteins Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism Up-Regulation - drug effects |
| title | Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A50%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Upregulating%20hsa-miR-128a%20Increased%20the%20Effects%20of%20Pembrolizumab%20on%20Laryngeal%20Cancer%20Cells%20via%20the%20p53%20Pathway&rft.jtitle=BioMed%20research%20international&rft.au=Chen,%20Hui&rft.date=2021&rft.volume=2021&rft.spage=2342784&rft.epage=6&rft.pages=2342784-6&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2021/2342784&rft_dat=%3Cgale_pubme%3EA696930489%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506098824&rft_id=info:pmid/33791361&rft_galeid=A696930489&rfr_iscdi=true |